Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q1 2021 · 10-Q
Revenue$173.10M$173.10M+5.5% vs Q1 2020 Net Income-$39.50M-$39.50MN/M vs Q1 2020 EPS Diluted-$0.52-$0.52N/M vs Q1 2020 Operating Income-$46,700,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Free Cash Flowderived$64,700,000+368.8% Margins · derivedOperating margin-27.0%+54.5 pt vs Q1 2020
Net margin-22.8%+47.4 pt vs Q1 2020
ended Mar 31, 2021 · filed May 5, 2021 · 35 d after period end